PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
Status:
Terminated
Trial end date:
2003-12-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if PEG-Intron is better tolerated and more
efficacious than standard interferons (Roferon, Intron) in patients with
Philadelphia-positive Chronic Myelogenous Leukemia. These patients should have previously
received standard interferon therapy and have been intolerant, resistant, or have relapsed
disease.